Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 15/20 | 0.47 |
| ▸ | PDE4A | P27815 | 5/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.47 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.42 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.42 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1871388 | 0.89 | PDE4B (0.47) | PDE4BPDE4APDE4CPDE4DNOTUM | |
| SCHEMBL23825806 | 0.88 | RBP4 (0.41) | PDE4BPDE4APDE4CPDE4DMAPT | |
| SCHEMBL28033753 | 0.87 | PDE4B (0.59) | PDE4BPDE4APDE4CPDE4DMAPT | |
| SCHEMBL29366131 | 0.87 | HTR4 (0.40) | PDE4BPDE4APDE4CPDE4DNOTUM | |
| SCHEMBL4510982 | 0.86 | PTGER4 (0.48) | PDE4BPDE4APDE4CPDE4DCNR2 | |
| SCHEMBL15541722 | 0.86 | PDE4B (0.46) | PDE4BPDE4APDE4CPDE4DCNR2 | |
| SCHEMBL4278555 | 0.84 | PDE4B (0.63) | PDE4BPDE4APDE4CPDE4DMAPT | |
| SCHEMBL29790148 | 0.84 | NOTUM (0.50) | PDE4BPDE4APDE4CPDE4DNOTUM | |
| SCHEMBL15650723 | 0.84 | CA12 (0.53) | PDE4BPDE4APDE4CPDE4DMAPT | |
| SCHEMBL2090601 | 0.84 | PDE4B (0.60) | PDE4BPDE4APDE4CPDE4DMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116102449-A | Phenyl derivatives as cannabinoid receptor 2 agonists | 豪夫迈·罗氏有限公司 | 2023-05-12 | — | — | CN | disclosed |
| CN-108349901-B | Phenyl derivatives as cannabinoid receptor 2 agonists | 豪夫迈·罗氏有限公司 | 2022-08-16 | — | — | CN | disclosed |
| US-11339120-B2 | Phenyl derivatives as cannabinoid receptor 2 agonists | HOFFMANN-LA ROCHE INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-11339120-B2 | Phenyl derivatives as cannabinoid receptor 2 agonists | HOFFMANN-LA ROCHE INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-20210171441-A1 | PHENYL DERIVATIVES AS CANNABINOID RECEPTOR 2 AGONISTS | HOFFMANN-LA ROCHE INC. (US) | 2021-06-10 | — | — | US | disclosed |
| US-20210171441-A1 | PHENYL DERIVATIVES AS CANNABINOID RECEPTOR 2 AGONISTS | HOFFMANN-LA ROCHE INC. (US) | 2021-06-10 | — | — | US | disclosed |
| EP-3386951-B1 | PHENYL DERIVATIVES AS CANNABINOID RECEPTOR 2 AGONISTS | HOFFMANN LA ROCHE (CH) | 2020-02-26 | — | — | EP | disclosed |
| EP-3386951-A1 | PHENYL DERIVATIVES AS CANNABINOID RECEPTOR 2 AGONISTS | H. Hoffnabb-La Roche Ag (CH) | 2018-10-17 | — | — | EP | disclosed |
| US-20180290966-A1 | PHENYL DERIVATIVES AS CANNABINOID RECEPTOR 2 AGONISTS | HOFFMANN-LA ROCHE INC. (US) | 2018-10-11 | — | — | US | disclosed |
| CN-108349901-A | PHENYL DERIVATIVES AS CANNABINOID RECEPTOR 2 AGONISTS | 豪夫迈·罗氏有限公司 | 2018-07-31 | — | — | CN | disclosed |
| WO-2017097732-A1 | PHENYL DERIVATIVES AS CANNABINOID RECEPTOR 2 AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2017-06-15 | — | — | WO | disclosed |
| WO-2017097732-A1 | PHENYL DERIVATIVES AS CANNABINOID RECEPTOR 2 AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2017-06-15 | — | — | WO | disclosed |
| WO-2010132016-A1 | BIS-(SULFONYLAMINO) DERIVATIVES FOR TREATMENT OF PAIN AND INFLAMMATION | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010132016-A1 | BIS-(SULFONYLAMINO) DERIVATIVES FOR TREATMENT OF PAIN AND INFLAMMATION | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | WO | disclosed |
| US-20100292279-A1 | Bis-(Sulfonylamino) Derivatives in Therapy | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | US | disclosed |
| US-20100292279-A1 | Bis-(Sulfonylamino) Derivatives in Therapy | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | US | disclosed |
| US-20100292279-A1 | Bis-(Sulfonylamino) Derivatives in Therapy | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171441-A1 | PHENYL DERIVATIVES AS CANNABINOID RECEPTOR 2 AGONISTS | CNR2, CNR1, GPR18 | PDE4B 704/4885PDE4A 719/4885PDE4C 1070/4885 |
| US-20180290966-A1 | PHENYL DERIVATIVES AS CANNABINOID RECEPTOR 2 AGONISTS | CNR2, CNR1, GPR18 | PDE4B 704/4885PDE4A 719/4885PDE4C 1070/4885 |
| US-11339120-B2 | Phenyl derivatives as cannabinoid receptor 2 agonists | CNR2, CNR1, GPR18 | PDE4B 704/4885PDE4A 719/4885PDE4C 1070/4885 |
| US-20100292279-A1 | Bis-(Sulfonylamino) Derivatives in Therapy | PTGER1, SULT2A1, SULT1E1 | PDE4B 1521/4885PDE4A 1098/4885PDE4C 2223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.